MAT Resources
Pfizer-BioNTech COVID-19 vaccine recommendation for New Mexicans 12 years of age and older
The New Mexico Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Pfizer-BioNTech COVID-19 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for...
Johnson & Johnson Janssen Ad26.COV2.S COVID-19 vaccine recommendation for New Mexicans
The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Janssen Ad26.COV2.S COVID-19 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for Disease...
Out-of-hospital infusion services for COVID-19 patients
The Medical Advisory Team updates its recommendation regarding out-of-hospital infusion services to manage the risk of infusion reactions in patients treated with intravenous therapies for COVID-19 infection: Personnel providing infusion therapy for COVID-19 should...
Moderna mRNA-1273 COVID-19 vaccine recommendation for New Mexicans
The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Moderna mRNA-1273 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for Disease Control...
Pfizer-BioNTech COVID-19 vaccine recommendation for New Mexicans
The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Work group has revised its recommendation to include additional guidance on the management of vaccine supply, including the full use of multi-dose vial contents that may contain more than 5 doses per vial....
Baricitinib (Olumiant) treatment for COVID-19 patients in NM
Baricitinib should be consider for use by healthcare providers, in combination with remdesivir (Veklury), to treat suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive...
REGN-COV2 treatment for COVID-19 patients in NM
Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible...
Increasing the number of COVID-19 patients who can be safely and effectively monitored and treated on an outpatient basis
This guidance is intended to assist with the outpatient management of patients with respiratory compromise who are clinically stable with moderate COVID-19 symptoms but who, if monitored on an outpatient basis, do not require hospitalization due to severity of...
Bamlanivimab distribution and treatment prioritization for COVID-19 patients in NM
Recommendations from the NM Medical Advisory Team include, but are not limited to: 1. Bamlanivimab should be distributed to centers with the capacity for intravenous administration and monitoring of outpatients who meet criteria of administration under the FDA...
Convalescent Plasma Treatment for COVID-19 Patients
In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who...